The Observational & Pragmatic Research Institute (OPRI) is proud to announce a new publication, ”What have we learnt from real-life research in asthma and COPD? Standards and novel designs for the future”.
“It is common for therapeutic guidelines to look to randomized controlled trials (RCTs) for evidence and insights as RCTs examine the efficacy of a clinical intervention,” said Professor Price. “But the strict eligibility criteria of RCTs means the average patient may not qualify for such studies. So, by using data from such patients, variables collected in routine care and larger populations, real-life research can answer so many questions that RCTs simply cannot. In fact, real-life research has impacted clinical guidelines.”
Examples of findings discussed in the commentary include the higher than anticipated prevalence of eosinophilic disease in broad and severe asthma, that short-acting beta-agonist (SABA) should not be prescribed alone and oral theophylline’s lack of value in reducing exacerbations among adults with COPD. Novel real-life study designs are set to answer important questions on earlier diagnosis and management of COPD as well.